

TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN¹

Type of respondent	Number of recordkeepers	Number of records per recordkeeper	Total annual records	Average burden per recordkeeper	Total hours
Domestic facilities	697	52	36,244	0.25 (15 minutes)	9,061
Foreign facilities	916	52	47,632	0.25 (15 minutes)	11,908
Total					20,969

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

Based on a review of the information collection since our last request for OMB approval, we have made no adjustments to our burden estimate.

Dated: August 10, 2020.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2020-17876 Filed 8-13-20; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Information Collection Request Title: Office for the Advancement of Telehealth Outcome Measures, OMB No. 0915-0311—Revision

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: In compliance with of the Paperwork Reduction Act of 1995, HRSA has submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30 day comment period for this notice has closed.

DATES: Comments on this ICR should be received within 30 days of this notice no later than September 14, 2020.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting "Currently under Review—Open for Public Comments" or by using the search function.

FOR FURTHER INFORMATION CONTACT: To request a copy of the clearance requests submitted to OMB for review, email the HRSA Information Collection Clearance Officer at paperwork@hrsa.gov or call (301) 443-1984.

SUPPLEMENTARY INFORMATION:

Information Collection Request Title: HRSA Telehealth Outcome Measures OMB No. 0915-0311—Revision.

Abstract: In order to help carry out its mission, the Office for the Advancement of Telehealth (OAT) created a set of performance measures that grantees can use to evaluate the effectiveness of their services programs and monitor their progress through the use of performance reporting data.

A 60-day Notice was published in the **Federal Register** on March 26, 2020, vol. 85, No. 59; p. 17089. There were no comments.

Need and Proposed Use of the Information: As required by the Government Performance and Results Act of 1993, all federal agencies must develop strategic plans describing their overall goal and objectives. The Federal Office of Rural Health Policy, OAT, has worked with its grantees to develop performance measures to be used to

evaluate and monitor the progress of the grantees. Grantee goals are to: Improve access to needed services; reduce rural practitioner isolation; improve health system productivity and efficiency; and improve patient outcomes. In each of these categories, specific indicators were designed to be reported through a performance monitoring website. New measures are being added to the Telehealth Network Grant Program to capture awardee-level and aggregate data that illustrate the impact and scope of federal funding along with assessing these efforts. The measures speak to OAT's progress toward meeting the goals, specifically telehealth services delivered through Emergency Departments.

Likely Respondents: Telehealth Network Grantees.

Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this Information Collection Request are summarized in the table below.

TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
Performance Improvement Measurement System (PIMS) ..	29	1	29	7	203
Total	29	29	203

Maria G. Button,

Director, Executive Secretariat.

[FR Doc. 2020–17787 Filed 8–13–20; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: Findings of research misconduct have been made against Rahul Dev Jayant, Ph.D. (Respondent), Assistant Professor Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Science Center (TTUHSC). Dr. Jayant engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), grant R03 DA044877. The administrative actions, including supervision for a period of three (3) years, were implemented beginning on July 27, 2020, and are detailed below.

FOR FURTHER INFORMATION CONTACT: Elisabeth A. Handley, Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453–8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Rahul Dev Jayant, Ph.D., Texas Tech University Health Science Center: Based on the report of an inquiry conducted by TTUHSC and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Jayant, Assistant Professor Pharmaceutical Sciences, School of Pharmacy, TTUHSC, engaged in research misconduct in research supported by PHS funds, specifically NIDA, NIH, grant R03 DA044877.

ORI found that Respondent engaged in research misconduct by intentionally plagiarizing, falsifying, and/or fabricating data included in the following grant applications submitted for PHS funds:

- R21 DA051845–01, “DAT–CNS Organoid–Chip Model to Characterize the Effects of Buprenorphine on Fetal Neurodevelopment,” submitted to NIDA, NIH, on October 16, 2019.
- R01 DA051894–01, “Novel 3D Printed CNS–Organoid Chip Model to

Elucidate HAND,” submitted to NIDA, NIH, on November 12, 2019.

- R21 DA052445–01, “3D Printed Microfluidic Chip Cerebral Organoids (3D–MCCO) to Decode Neurodevelopmental Deficits with Oxycodone Exposure,” submitted to NIDA, NIH, on February 10, 2020.
- R21 AA028877–01, “3D Printed CNS–Organoid Chip Model to Identify Biomarkers for Prenatal Alcohol Exposure,” submitted to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH, on February 13, 2020.

ORI found that Respondent engaged in research misconduct by intentionally:

- Plagiarizing four (4) images of brain organoids and one (1) graph from *Nat Protoc.* 2014 Oct; 9(10):2329–40 (hereafter referred to as “NP 2014”) without author attribution and including the plagiarized material in Figure 3iia–c of R21 DA051845–01, Figure 2iiaa–c of R01 DA051894–01, Figure 3iiaa–c of R21 DA052445–01, Figure 3iiaa–c of R21 AA028877–01, and the graph in Figure 2iv of R01 DA051894–01.

- Plagiarizing one (1) image of brain organoids from *Nature Communications* 2018 Oct 9; 9(1):4167 (hereafter referred to as “NC 2018”) without author attribution and including the plagiarized material in Figure 2iiaa of R01 DA051894–01.

- Falsifying and fabricating three (3) figures representing experiments measuring caspase3 expression in human brain organoids by reusing data from one experiment to represent different experimental treatments in Figure 4Bii of R21 DA051845–01, Figure 4iv of R21 DA052445–01, and Figure 3iii of R21 DA051894–01.

- Fabricating nine (9) bar graphs representing experiments measuring gene expression in control and experimental samples of human brain organoids treated with drugs of abuse in Figures 2i and 3i–iii of R21 DA051894–01, Figures 3ii, 4Ai–ii, and 4Bii of R21 AA028877–01, Figures 3ii and 4i–iii of R21 DA052445–01, and Figures 4A, 4Bi, and 5 of R21 DA051845–01.

Specifically, ORI found that Respondent intentionally:

- Plagiarized confocal images of immuno-stained samples of human brain organoids from Figure 4 of NP 2014, and the plagiarized images were cropped, rotated, contrast enhanced and labeled with scale bars in:
 - Figure 3iia–c in R21 DA051845–01
 - Figure 2iiaa–c in R01 DA051894–01
 - Figure 3iiaa–c in R21 DA052445–01
 - Figure 3iiaa–c in R21 AA028877–01
- Plagiarized confocal images of immuno-stained samples of human

brain organoids from Figure 1e of NC 2018 in Figure 2iiaa in R01 DA051894–01. The plagiarized image was cropped and rotated and the contrast was altered.

- Plagiarized the graph in Figure 2iv in R01 DA051894–01 representing measurements of gene expression and associated statistics in cultured human brain organoids. The source of the plagiarized graph is unknown.
- Plagiarized the graph in Figure 2iv in R01 DA051894–01 representing measurements of gene expression and associated statistics in cultured human brain organoids. The source of the plagiarized graph is unknown.

- Falsified and fabricated control and experimental data representing measurements of caspase3 mRNA expression in human brain organoids treated with drugs of abuse. The identical images were falsely relabeled to represent different experimental treatments that were never done. The identical panels are:

- Figure 4Bii, labeled as “Buprenorphine (5 μ M),” in R21 DA051845–01
- Figure 4iv, labeled as “Oxy 10 μ M,” in R21 DA052445–01
- Figure 3iii, labeled as “Meth-10 μ M,” in R21 DA051894–01

- Falsified Figure 4Bi in R21 AA028877–01 to represent control and experimental data measuring neurite outgrowth in cultured human neurons treated with ethanol. The panels in Figure 4Bi in R21 DA051894–01, labeled as control or treated with 10ng/ml Tat for 1 or 7 days, are identical to those in Figure 4Bi in R21 AA028877–01, which were falsely relabeled as control or treated with 10 or 40 mM EtOH.

- Fabricated quantitative data and associated statistics representing measurements of gene expression levels in cultured human brain organoids over time or treated with drugs of abuse.

The fabricated bar graphs are:

- Figures 2i and 3i–iii in R21 DA051894–01
- Figures 3ii, and 4Ai–ii, and 4Bii in R21 AA028877–01
- Figures 3ii and 4i–iii in R21 DA052445–01
- Figures 4A, Bi, and 5 in R21 DA051845–01

Dr. Jayant entered into a Voluntary Settlement Agreement and agreed to the following:

- (1) Respondent agreed to have his research supervised for a period of three (3) years beginning on July 27, 2020. Respondent agreed that prior to the submission of an application for PHS support for a research project on which Respondent’s participation is proposed